Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

red number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our actual burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

                            BIOCRYST PHARMACEUTICALS, INC.
                                  FINANCIAL SUMMARY

    Statements of Operations (Unaudited)
      (in thousands,
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
(Date:9/22/2014)... University of Manchester have generated a new star-shaped molecule made ... its kind ever created. , Known as a ... one for over a quarter of a century and the ... . , Consisting of two molecular triangles, entwined about ... molecules are tiny each triangle is 114 atoms in ...
(Date:9/22/2014)... September 22, 2014 Lawrence Livermore ... John DeGioia on Friday renewed their institutional commitment ... additional five years to expand the collaborative work ... and global climate, energy and environmental sciences. , ... MOU originally signed in December 2009 and is ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Topical ... helping those in pain end their suffering, restoring hope ... healthcare model. This is only possible because of the ... and healing cream technology a reality. , The ... Rhinebeck, NY, by Lou Paradise (president, chief of research, ...
Breaking Biology Technology:Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... produced in barley grain, using renewable,geothermal energy, ... Genetics,( http://www.orfgenetics.com ), an Icelandic biotechnology company, ... 22,000 ft^2 (2043m^2),cultivation facilities in Grindavik, Iceland. ... barley, ORF Genetics produces and,markets biorisk-free ISOkine(TM) ...
... Stock Exchange Symbol: MS, EDMONTON, May 13 /PRNewswire-FirstCall/ - ... of multiple sclerosis (MS), today,announced that Dr. Mark Krantz, Vice ... Oligonucleotide and Peptide,Technology and Product Development Conference in Las Vegas., ... at 10:45 am (PDT), WHERE: Red ...
... Pharmaceuticals Founder and Senior Management Form Company ... Specializing in Dermatology and Podiatry Markets, FAIRFIELD, N.J., ... commenced operations. The newly-formed,Company, led by the founder and ... (NYSE: BDY ), will develop, license and,commercialize innovative ...
Cached Biology Technology:ORF Genetics Opens Revolutionary 'Green Factory' in Iceland 2BioMs Medical to present at TIDES(R) Conference 2Medimetriks Pharmaceuticals, Inc. Begins Operations 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... study the unique bioelectric signaling system of the electric ... The OU researcher is working to understand how ... signals used to map the world around them. ... 500-600 discharges a second throughout their lives. The ... but necessary for survival. , "There is evidence that ...
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... the first time, traced the nanoparticles taken up from ... states of their metallic elements. Zinc was shown to ... cerium did not dissolve into plant tissue. The results ... nanoparticles and whether engineered nanoparticles can enter into the ...
... JOLLA, CA----You might think you have nothing in common ... a plant from the mustard family, Salk scientists have ... directly regulate chemical reactions that quickly adjust the growth ... different body parts coordinate their growth, shedding light on ...
... the performance of technologies ranging from medical CT scanners ... extract specific information from huge collections of data and ... new approach is called model-based iterative reconstruction, or MBIR. ... and error, assessing probability and discarding extraneous information," said ...
Cached Biology News:X-rays reveal uptake of nanoparticles by soya bean crops 2X-rays reveal uptake of nanoparticles by soya bean crops 3Plants cut the mustard for basic discoveries in metabolism 2Plants cut the mustard for basic discoveries in metabolism 3New modeling approach transforms imaging technologies 2New modeling approach transforms imaging technologies 3New modeling approach transforms imaging technologies 4
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... Analysis Note: Evaluated for its amino acid ... of amino acids Ala, Asp, Gly, Ile, Lys, ... Ser, Tyr. Preparation Unit Definition: One unit will ... 1.0 ml of water (1 cm light path). ...
... use as a carrier in ... Physical form: Solution in 10 ... 1 mM EDTA Preparation Note: ... Concentration: 10 mg/mL ...
... Cleland’s Reagent, Immobilized White solid. ... form of DTT on polyacrylamide resin with applications ... 233153 , 233156 , and ... no soluble components are added to the system. ...
Biology Products: